Table 1.

Baseline characteristics of antianginal medication users and nonusers, by each medication group

	Any Kind of Drug		β‐Blocker		CCB		Long‐acting Nitrate		Ranolazine
	Yes (n = 4996)	No (n = 612)	Yes (n = 4629)	No (n = 979)	Yes (n = 2294)	No (n = 3314)	Yes (n = 1685)	No (n = 3923)	Yes (n = 65)	No (n = 5543)
Age, y, median (IQR)	65 (57–73)	63 (56–71)	65 (57–73)	64 (57–72)	66 (58–74)	64 (56–72)	66 (57–73)	65 (57–72)	69 (60–75)	65 (57–73)
Female sex	32	30	32	31	37	29	36	30	34	32
HTN	78	67	78	71	83	72	81	75	86	77
Hyperlipidemia	70	68	70	68	70	70	72	69	80	70
DM	35	31	36	31	39	32	38	33	37	35
PVD	12	9	12	10	14	10	14	11	22	11
History of MI	31	26	32	23	28	32	34	29	42	30
Typical chest pain	71	58	71	60	69	70	71	69	76	69
Positive stress test	59	56	59	57	57	60	57	60	46	59
Number of 3‐vessel disease	37	31	38	30	38	35	43	33	45	36
Revascularization (PCI/CABG) within 30 days post‐catheterization	59	23	60	34	62	51	52	57	49	55

Abbreviations: CABG, coronary artery bypass grafting; CCB, calcium channel blocker; DM, diabetes mellitus; HTN, hypertension; IQR, interquartile range; MI, myocardial infarction; NSTEMI, non–ST‐segment elevation myocardial infarction; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; STEMI, ST‐segment elevation myocardial infarction.

All values are reported as % unless otherwise specified.